Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

NCT01596751 is registered in ClinicalTrials.gov with Hope Rugo, MD as lead sponsor.

NCT NCT01596751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01596751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Lead sponsor
Hope Rugo, MD
Phase
Phase 1/2
Overall status
Completed
Start date
July 12, 2012
Completion date
July 5, 2019
Enrollment
67 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer